The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (Avastin)

Results 

Thirty-eight patients were included. All patients were heavily pre-treated with a median of five prior regimens. ..... The VEGF serum level decreased during treatment in all patients. A low pre-treatment VEGF level was predictive to response. 

Conclusions

Single agent bevacizumab has activity in ovarian cancer patients. Pre-treatment serum VEGF seems to have predictive value.